Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing U.S.-based Bio-Techne...
Purchase price of US$73 per share in cash represents an enterprise value of US$11.3 billion (EUR 9.9 billion) Proposed acquisition expected to be immediately accretive to sales growth and EBITDA pre margin post-closing, and EPS pre accretive by year 3 after closing U.S.-based Bio-Techne...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.